Context Therapeutics^® and Wisconsin Oncology Network Announce First Patient Dosed in Phase II Trial of ONA-XR in Metastatic Breast Cancer

Context Therapeutics, Inc. announced the first patient has been dosed in the Phase II Trial of Onapristone in combination with Fulvestrant for patients with ER-positive, and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 Inhibitors.